Switch to:
More From Other Websites
Regeneron Pharmaceuticals’ Major Revenue Sources in 4Q15 Feb 12 2016
Bad News for Regeneron Pharmaceuticals for 4Q15 Revenue and Earnings Feb 12 2016
Express Scripts sees slow 2016 sales for new cholesterol drugs Feb 12 2016
REGENERON PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Feb 11 2016
Morgan Stanley is Wrong: This Biotech is Ready to Explode Higher Feb 11 2016
The Zacks Analyst Blog Highlights: Regeneron, Alexion, CTI BioPharma, BioCryst and Sarepta Feb 11 2016
Novartis And the Future Of Drug Pricing Feb 10 2016
Biotech Stock Roundup: Alexion, Regeneron Miss Estimates; Setback for CTI BioPharma Feb 10 2016
Regeneron Pharmaceuticals, Inc. Earnings Analysis: 2015 By the Numbers Feb 10 2016
Regeneron Q4 Earnings Miss Estimates Amid Slow Praluent Launch Feb 09 2016
[$$] Regeneron: Good Results, Great Expectations Feb 09 2016
Edited Transcript of REGN earnings conference call or presentation 9-Feb-16 1:30pm GMT Feb 09 2016
Regeneron Q4 Earnings Lag, Gives 2016 View for Eylea Sales Feb 09 2016
Regeneron sees gradual adoption of cholesterol drug Praluent Feb 09 2016
Regeneron: Get Used to Disappointment Feb 09 2016
US STOCKS-Wall St turn positive after weak start as tech rebounds Feb 09 2016
Stocks to Watch: Regeneron, Sears, Coke, XPO Feb 09 2016
Regeneron Falls on Missed Earnings Feb 09 2016
Regeneron (REGN) Misses on Q4 Earnings and Revenues Feb 09 2016
US STOCKS-Wall St set for lower open as investors seek safety Feb 09 2016
Regeneron misses Street 4Q forecasts Feb 09 2016
Regeneron to Report Fourth Quarter and Full Year 2015 Financial and Operating Results and Host... Jan 26 2016
Regeneron and Sanofi Announce Sarilumab Biologics License Application Accepted for Review by US FDA Jan 08 2016
Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA Jan 08 2016
Regeneron Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference Jan 07 2016
Sanofi and Regeneron Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® (alirocumab)... Nov 24 2015
Regeneron Celebrates Patient Innovation and Growth in New York State Nov 12 2015
Regeneron and Sanofi Present Results from Pivotal Phase 3 Study of Sarilumab at American College of... Nov 08 2015
Regeneron Reports Third Quarter 2015 Financial and Operating Results Nov 04 2015
Regeneron beats Street 3Q forecasts Nov 04 2015
Regeneron Announces EU Approval of EYLEA® (aflibercept) Injection for the Treatment of Visual... Oct 30 2015
Regeneron Announces Presentation at the 24th Annual Credit Suisse Healthcare Conference Oct 23 2015
Regeneron Announces an Additional $350 Million Investment and 200 New Jobs in Limerick by End-2017 Oct 19 2015
Regeneron to Report Third Quarter 2015 Financial and Operating Results and Host Conference Call and... Oct 08 2015
Regeneron and Sanofi Announce Publication of Positive Phase 2b Dupilumab Data in The Lancet Oct 08 2015
Regeneron Announces Collaboration with Mitsubishi Tanabe Pharma for Investigational Pain Therapy... Oct 01 2015
Sanofi and Regeneron Announce Approval of Praluent® (alirocumab) for the Treatment of... Sep 28 2015
Regeneron and Icahn School of Medicine at Mount Sinai Announce New Antibody Research Agreement Sep 24 2015
Regeneron Announces Agreement with BARDA for the Development of New Antibody Treatment for Ebola Sep 21 2015
Regeneron Hires Maya Bermingham as Executive Director, Public Policy Sep 10 2015
Regeneron Discovery on Cause of Rare Genetic Bone Disease Detailed in Science Translational Medicine... Sep 02 2015
Regeneron and Sanofi Announce New Positive Praluent® (alirocumab) Phase 3 Data Presented at ESC... Sep 01 2015
Amgen wins approval for second biotech cholesterol drug Aug 27 2015
US STOCKS-Wall St flat amid slew of earnings, Apple weighs Aug 04 2015
Regeneron tops Street 2Q forecasts Aug 04 2015
Express Scripts excludes 20 more drugs from 2016 coverage Jul 31 2015
FDA panel backs Amgen cholesterol drug for some patients Jun 10 2015
US stocks surge as tech, banking sectors lead Jun 10 2015
FDA panel backs first-in-class cholesterol drug Jun 09 2015
FDA weighs approval of first-in-class cholesterol drug Jun 05 2015
Regeneron tops Street 1Q forecasts May 07 2015
Amgen tops estimates with 51 percent spike in 1Q profit Apr 21 2015
U.S. stocks slip, dollar gains day after Fed view Mar 19 2015
GLOBAL MARKETS-U.S. stocks slip, dollar gains day after Fed view Mar 19 2015
GLOBAL MARKETS-U.S. stocks slip, dollar gains day after Fed view Mar 19 2015
Regeneron misses 4Q profit forecasts Feb 10 2015
New data fuels doctors' demands to rewrite U.S. heart guidelines Nov 21 2014
Sanofi touts new drugs but diabetes outlook disappoints Nov 20 2014
Sanofi's dual-action biotech asthma drug performs well in test Nov 11 2014
Sanofi's dual-action biotech asthma drug performs well in test Nov 11 2014
US STOCKS-Wall St slips as energy extends recent slide Nov 04 2014
Regeneron falls after paring Eylea sales outlook Nov 04 2014
US STOCKS-Futures point to lower open, energy shares in view Nov 04 2014
Regeneron, Sanofi say sinusitis drug met goals Sep 30 2014
US STOCKS-Biotech shares drop, Amarin plunges 20 pct Sep 12 2014
US STOCKS-S&P 500 tops 2,000; analysts see more gains ahead Aug 25 2014
Sanofi lifts 2014 guidance after second quarter earnings beat expectations Jul 31 2014
US STOCKS-S&P 500, Nasdaq end up as Fed in no rush to raise rates Jul 30 2014
US STOCKS-S&P 500 nearly flat as investors digest Fed statement Jul 30 2014
US STOCKS-S&P 500 turns higher after Fed statement Jul 30 2014
Sanofi, Regeneron drug cuts cholesterol in nine late-stage trials Jul 30 2014
Sanofi raises stake in Regeneron; shares jump Jul 01 2014


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK